Addendum: The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.

Hassanipour, Soheil; Arab-Zozani, Morteza; Amani, Bahman; Heidarzad, Forough; Fathalipour, Mohammad; Martinez-de-Hoyo, Rudolph

Hassanipour, Soheil; Arab-Zozani, Morteza; Amani, Bahman; Heidarzad, Forough; Fathalipour, Mohammad; Martinez-de-Hoyo, Rudolph.

Hassanipour S; Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Arab-Zozani M; Social Determinants of Health Research Center, Birjand University of Medical Sciences, Birjand, Iran. arab.hta@gmail.com.
Amani B; Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran.
Heidarzad F; Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran.
Fathalipour M; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Martinez-de-Hoyo R; MSN Labs Americas, Bogotá, Colombia.

Sci Rep ; 12(1): 1996, 2022 02 01.

Article in English | MEDLINE | ID: covidwho-1665720

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study / Reviews / Systematic review/Meta Analysis Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-05835-2

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google